The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children
BackgroundMultisystem Inflammatory Syndrome in Children (MIS-C) is a severe, life threatening, complication that arises weeks after acute Coronavirus disease 2019 (COVID-19) infection, often presenting with fever and diverse systemic symptoms. Limited data exists on the effectiveness of biologic and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1607637/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849317685755641856 |
|---|---|
| author | Lana Khoury Adi Miller-Barmak Adi Miller-Barmak Shereen Shehadeh Shereen Shehadeh Shereen Shehadeh Hilla Cohen Dana Hadar Mohamad Hamad Saied Mohamad Hamad Saied Mohamad Hamad Saied |
| author_facet | Lana Khoury Adi Miller-Barmak Adi Miller-Barmak Shereen Shehadeh Shereen Shehadeh Shereen Shehadeh Hilla Cohen Dana Hadar Mohamad Hamad Saied Mohamad Hamad Saied Mohamad Hamad Saied |
| author_sort | Lana Khoury |
| collection | DOAJ |
| description | BackgroundMultisystem Inflammatory Syndrome in Children (MIS-C) is a severe, life threatening, complication that arises weeks after acute Coronavirus disease 2019 (COVID-19) infection, often presenting with fever and diverse systemic symptoms. Limited data exists on the effectiveness of biologic and targeted-synthetic therapies in preventing MIS-C development. Therefore, our aim was to investigate whether biologic and targeted-synthetic therapies can prevent the occurrence of MIS-C.MethodsWe assessed the Clalit Health Services database, the largest health care organization in Israel, data from 793,909 children aged 0–18 years who tested positive for COVID-19 were analyzed. The diagnosis of MIS-C was adjudicated using the case definition used by the Centers for Disease Control and Prevention (CDC) or by the World Health Organization (WHO). Patients receiving biologic and targeted-synthetic therapies were compared to a control group.ResultsAmong 793,909 cases, 573 children received biologic and targeted-synthetic therapies, and 143 cases of MIS-C were identified. Notably, none of the individuals treated with biologic and targeted-synthetic therapies developed MIS-C.ConclusionOur study highlights our hypothesis on the efficacy of biological treatments in preventing MIS-C. Although statistical significance was not achieved due to the absence of MIS-C cases in patients receiving biologic and targeted-synthetic therapies, our study shows a possible association between biological therapies and reduced risk of MIS-C following COVID-19 infection in children. Further research, including prospective studies with larger cohorts, is warranted to confirm these findings and elucidate underlying mechanisms. |
| format | Article |
| id | doaj-art-c27691bf9cb747f2bef01e4f9363cd5f |
| institution | Kabale University |
| issn | 2296-2360 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj-art-c27691bf9cb747f2bef01e4f9363cd5f2025-08-20T03:51:08ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602025-07-011310.3389/fped.2025.16076371607637The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in childrenLana Khoury0Adi Miller-Barmak1Adi Miller-Barmak2Shereen Shehadeh3Shereen Shehadeh4Shereen Shehadeh5Hilla Cohen6Dana Hadar7Mohamad Hamad Saied8Mohamad Hamad Saied9Mohamad Hamad Saied10Department of Pediatrics, Carmel Medical Center, Haifa, IsraelDepartment of Pediatrics, Carmel Medical Center, Haifa, IsraelPediatric Rheumatology Service, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, IsraelDepartment of Pediatrics, Carmel Medical Center, Haifa, IsraelPediatric Infectious Unit, Carmel Medical Center, Haifa, IsraelRappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelResearch Authority, Clalit Health Care Organization, Carmel Medical Center, Haifa, IsraelResearch Authority, Clalit Health Care Organization, Carmel Medical Center, Haifa, IsraelDepartment of Pediatrics, Carmel Medical Center, Haifa, IsraelRappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelDepartment of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, NetherlandsBackgroundMultisystem Inflammatory Syndrome in Children (MIS-C) is a severe, life threatening, complication that arises weeks after acute Coronavirus disease 2019 (COVID-19) infection, often presenting with fever and diverse systemic symptoms. Limited data exists on the effectiveness of biologic and targeted-synthetic therapies in preventing MIS-C development. Therefore, our aim was to investigate whether biologic and targeted-synthetic therapies can prevent the occurrence of MIS-C.MethodsWe assessed the Clalit Health Services database, the largest health care organization in Israel, data from 793,909 children aged 0–18 years who tested positive for COVID-19 were analyzed. The diagnosis of MIS-C was adjudicated using the case definition used by the Centers for Disease Control and Prevention (CDC) or by the World Health Organization (WHO). Patients receiving biologic and targeted-synthetic therapies were compared to a control group.ResultsAmong 793,909 cases, 573 children received biologic and targeted-synthetic therapies, and 143 cases of MIS-C were identified. Notably, none of the individuals treated with biologic and targeted-synthetic therapies developed MIS-C.ConclusionOur study highlights our hypothesis on the efficacy of biological treatments in preventing MIS-C. Although statistical significance was not achieved due to the absence of MIS-C cases in patients receiving biologic and targeted-synthetic therapies, our study shows a possible association between biological therapies and reduced risk of MIS-C following COVID-19 infection in children. Further research, including prospective studies with larger cohorts, is warranted to confirm these findings and elucidate underlying mechanisms.https://www.frontiersin.org/articles/10.3389/fped.2025.1607637/fullMIS-CCOVID-19biological treatmentspediatrictargeted-synthetic therapies |
| spellingShingle | Lana Khoury Adi Miller-Barmak Adi Miller-Barmak Shereen Shehadeh Shereen Shehadeh Shereen Shehadeh Hilla Cohen Dana Hadar Mohamad Hamad Saied Mohamad Hamad Saied Mohamad Hamad Saied The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children Frontiers in Pediatrics MIS-C COVID-19 biological treatments pediatric targeted-synthetic therapies |
| title | The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children |
| title_full | The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children |
| title_fullStr | The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children |
| title_full_unstemmed | The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children |
| title_short | The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children |
| title_sort | protective effect of biologic and targeted synthetic therapies on developing multisystem inflammatory syndrome in children |
| topic | MIS-C COVID-19 biological treatments pediatric targeted-synthetic therapies |
| url | https://www.frontiersin.org/articles/10.3389/fped.2025.1607637/full |
| work_keys_str_mv | AT lanakhoury theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT adimillerbarmak theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT adimillerbarmak theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT hillacohen theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT danahadar theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied theprotectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT lanakhoury protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT adimillerbarmak protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT adimillerbarmak protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT shereenshehadeh protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT hillacohen protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT danahadar protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren AT mohamadhamadsaied protectiveeffectofbiologicandtargetedsynthetictherapiesondevelopingmultisysteminflammatorysyndromeinchildren |